GSK3 inhibitor suppresses cell growth and metabolic process in FLT3-ITD leukemia cells

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Glycogen Synthase Kinase-3 (GSK-3) plays a role in acute myeloid leukemia (AML) pathogenesis.
• FLT3-ITD mutations are common in AML and associated with poor prognosis.

Purpose of the Study:

• To investigate the therapeutic potential of GSK-3 inhibitors, specifically BIO, in FLT3-ITD mutated AML.
• To elucidate the mechanisms by which BIO affects AML cell proliferation, apoptosis, and metabolism.

Main Methods:

• In vitro treatment of MV4-11 AML cells with GSK-3 inhibitors (SB216763 and BIO).
• Cell cycle analysis, apoptosis assays, and Western blotting to assess molecular changes.
• In vivo studies using mouse models to evaluate tumor growth suppression.
• Metabolomics analysis to investigate metabolic pathway alterations.

Main Results:

• Low concentrations of GSK-3 inhibitors suppressed AML cell proliferation.
• BIO demonstrated higher efficacy than SB216763, inducing G1 cell cycle arrest and apoptosis.
• BIO reduced ATP and pyruvate levels, indicating partial inhibition of glycolysis.
• In vivo, BIO suppressed tumor growth in AML models.

Conclusions:

• BIO effectively suppresses proliferation and induces apoptosis in FLT3-ITD AML cells.
• Partial inhibition of glycolysis is a key mechanism of BIO's anti-leukemic activity.
• BIO represents a promising therapeutic candidate for AML treatment.